These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 31075939)

  • 81. Extracellular vesicle-mediated transport: Reprogramming a tumor microenvironment conducive with breast cancer progression and metastasis.
    Brena D; Huang MB; Bond V
    Transl Oncol; 2022 Jan; 15(1):101286. PubMed ID: 34839106
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Integrative Analysis of Breast Cancer Cells Reveals an Epithelial-Mesenchymal Transition Role in Adaptation to Acidic Microenvironment.
    Sadeghi M; Ordway B; Rafiei I; Borad P; Fang B; Koomen JL; Zhang C; Yoder S; Johnson J; Damaghi M
    Front Oncol; 2020; 10():304. PubMed ID: 32211331
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Tumor microenvironment pathways: Cross regulation in breast cancer metastasis.
    Malla RR; Kiran P
    Genes Dis; 2022 Mar; 9(2):310-324. PubMed ID: 35224148
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Emerging Autophagy Functions Shape the Tumor Microenvironment and Play a Role in Cancer Progression - Implications for Cancer Therapy.
    Bustos SO; Antunes F; Rangel MC; Chammas R
    Front Oncol; 2020; 10():606436. PubMed ID: 33324568
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Tumour Microenvironment-Immune Cell Interactions Influencing Breast Cancer Heterogeneity and Disease Progression.
    Tan K; Naylor MJ
    Front Oncol; 2022; 12():876451. PubMed ID: 35646658
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Epithelial-mesenchymal transition in pancreatic carcinoma.
    Maier HJ; Wirth T; Beug H
    Cancers (Basel); 2010 Dec; 2(4):2058-83. PubMed ID: 24281218
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The effect of TWIST silencing in metastatic chordoma cells.
    Aydemir E; Kaşikci E; Coşkunçelebi B; Bayrak ÖF; Şahin F
    Turk J Biol; 2018; 42(4):279-285. PubMed ID: 30814891
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Tumor microenvironment heterogeneity: challenges and opportunities.
    Runa F; Hamalian S; Meade K; Shisgal P; Gray PC; Kelber JA
    Curr Mol Biol Rep; 2017 Dec; 3(4):218-229. PubMed ID: 29430386
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Propensity for Early Metastatic Spread in Breast Cancer: Role of Tumor Vascularization Features and Tumor Immune Infiltrate.
    D'Andrea MR; Cereda V; Coppola L; Giordano G; Remo A; De Santis E
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885027
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The Contribution of Race to Breast Tumor Microenvironment Composition and Disease Progression.
    Kim G; Pastoriza JM; Condeelis JS; Sparano JA; Filippou PS; Karagiannis GS; Oktay MH
    Front Oncol; 2020; 10():1022. PubMed ID: 32714862
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Role of the complement system in the tumor microenvironment.
    Zhang R; Liu Q; Li T; Liao Q; Zhao Y
    Cancer Cell Int; 2019; 19():300. PubMed ID: 31787848
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Analysis of immune subtypes across the epithelial-mesenchymal plasticity spectrum.
    Chakraborty P; Chen EL; McMullen I; Armstrong AJ; Kumar Jolly M; Somarelli JA
    Comput Struct Biotechnol J; 2021; 19():3842-3851. PubMed ID: 34306571
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Cellular Plasticity in Breast Cancer Progression and Therapy.
    Kong D; Hughes CJ; Ford HL
    Front Mol Biosci; 2020; 7():72. PubMed ID: 32391382
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Editorial: Cancer Plasticity and the Microenvironment: Implications for Immunity and Therapy Response.
    Behren A; Thompson EW; Anderson RL; Ferrao PT
    Front Oncol; 2019; 9():276. PubMed ID: 31134142
    [No Abstract]   [Full Text] [Related]  

  • 95. Overcoming EMT-driven therapeutic resistance by BH3 mimetics.
    Keitel U; Scheel C; Dobbelstein M
    Oncoscience; 2014; 1(11):706-8. PubMed ID: 25593997
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment.
    Li JJ; Tsang JY; Tse GM
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439387
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Curcuminoids as Modulators of EMT in Invasive Cancers: A Review of Molecular Targets With the Contribution of Malignant Mesothelioma Studies.
    Pouliquen DL; Boissard A; Henry C; Coqueret O; Guette C
    Front Pharmacol; 2022; 13():934534. PubMed ID: 35873564
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response.
    Wang G; Xu D; Zhang Z; Li X; Shi J; Sun J; Liu HZ; Li X; Zhou M; Zheng T
    NPJ Precis Oncol; 2021 Jun; 5(1):56. PubMed ID: 34158591
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Smart Nanoparticles for Breast Cancer Treatment Based on the Tumor Microenvironment.
    Luo X; Zhang Q; Chen H; Hou K; Zeng N; Wu Y
    Front Oncol; 2022; 12():907684. PubMed ID: 35720010
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Induced electric fields inhibit breast cancer growth and metastasis by modulating the immune tumor microenvironment.
    Charan M; Jones TH; Ahirwar DK; Acharya N; Subramaniam VV; Ganju RK; Song JW
    bioRxiv; 2024 Apr; ():. PubMed ID: 38659909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.